Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Nichols shares dip on margin squeeze

(Sharecast News) - Vimto cordial producer Nichols published its interim results on Thursday, which showed continued strategic progress but also flagged margin pressure and a more cautious capital return approach. Group revenues edged up 1.8% to £85.5m in the six months ended 30 June, while adjusted operating profits rose 4.1% to £13.6m. However, adjusted pre-tax profits increased just 0.8% to £14.6m, with margins narrowing slightly due to reduced interest income and higher exceptional costs.

International sales fell 2.5% overall, weighed down by shipment phasing in the Middle East, though African revenue surged 16.9% on the back of a shift to a concentrate model.

UK packaged sales grew 3.7%, supported by volume gains and the launch of its vitamin-enriched squash, Wonderfuel, while out-of-home revenue rose 1.9%.

Howver, despite solid free cash flow of £14.2m and net cash of £61.6m, Nichols voted against declaring a special dividend, following last year's £20m payout, and instead, opted for a modest 15.0p interim dividend, up just 0.7% year-on-year.

Looking ahead, Nichols said FY adjusted pre-tax profits were expected to be in line with market expectations, but cautioned that ongoing economic uncertainty and tax changes both posed potential headwinds

As of 1015 BST, Nichols shares were down 2.58% at 1,359p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.